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Abstract
AIM: To analyze the expression of 8 putative cancer 
stem cell (CSC) markers within colorectal cancer tumor 
buds and to determine their prognostic impact in 
patients with this disease. 
METHODS: Immunohistochemistry was performed on 
101 colorectal cancer resections for CK22 (to identify 
tumor buds) as well as CD133, CD166, CD24, CD44s, 
CD90, EpCAM, ALDH1, and ABCG5, and their expression 
within tumor buds was evaluated. 
RESULTS: CD90, CD44s, and CD133 expression in 
tumor buds was found in less than 5% of all cases. 
ALDH1, CD24, CD166 were expressed in 16.5%, 16.2%, 
and 34% cases, respectively, while ABCG5 and EpCAM 
expression was more frequent and found in 35% and 
69% of cases, respectively. Of the 8 markers studied, 
EpCAM and ABCG5 positivity in tumor buds were 
significantly associated with poor prognosis (P = 0.023, 
P  = 0.038, respectively) in multivariable analysis with pT 
and pN classification [P = 0.048; hazard ratio (HR): 2.64; 
95% CI: 1.0-6.9, for EpCAM and P  = 0.029; HR: 2.22; 
95% CI: 1.0-4.5, for ABCG5]. Poor survival time was 
particularly striking for lymph node-negative patients 
with ABCG5-positive buds (P  < 0.001). 
CONCLUSION: Expression of putative stem cell markers 
EpCAM and ABCG5 within the tumor buds of colorectal 
cancer are frequently noted and are associated with 
poor prognosis. 
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
In 1985, Gabbert and colleagues described a peculiar 
feature at the invasive border of  differentiated colonic 
tumors: neoplastic glands irregularly arranged into small 
strands or single cells without junctional complexes and 
often missing even rudimentary basement membranes[1,2]. 
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Their observation of  the tumor front of  differentiated 
adenocarcinomas focally acquiring the phenotype of  
undifferentiated tumors is credited for pioneering the 
concept commonly referred to today as epithelial mesen­
chymal transition (EMT) and represented in colorectal 
cancer by its histological hallmark “tumor budding”. 
Defined as single cells or clusters of  up to 4 or 5 cells 
at the invasive tumor front, tumor budding can easily 
be spotted using pan­cytokeratin stains and is highly 
associated with an infiltrating tumor border configuration[3]. 
The adverse prognostic impact of  tumor budding in 
colorectal cancer has consistently been reported and recog­
nized by the American Joint Committee on Cancer/Union 
International Contre le Cancer (AJCC/UICC) as an addi­
tional prognostic factor to complement Tumor Node 
Metastases (TNM) staging[4-13]. Moreover, tumor budding 
is frequently linked to high­grade tumors, lymph node 
positivity, vascular and lymphatic invasion, as well as to 
both local tumor recurrence and distant metastasis[11,14-17]. 
Several lines of  evidence seem to suggest that tumor 
buds may, to some extent, represent malignant colorectal 
cancer stem cells (CSC) because of  their potential for 
migration and re­differentiation locally and at sites of  
metastasis[18]. “Pseudopodia­like” cytoplasmic protrusions 
have been described in tumor buds, which seem to be in 
direct contact with adjacent interstitial tissue suggesting 
their formation during cell migration[2,19,20]. Previous 
studies on EMT and events occurring at the invasive 
tumor front implicate, in particular, Wnt pathway signaling 
in the process of  tumor budding[21]. This is evidenced 
by increased β­catenin immunohistochemical staining in 
tumor buds, a concomitant loss of  E­cadherin, as well 
as overexpression of  laminin5γ2 along with activation 
of  transcriptional repressors SLUG, and ZEB1[19,22,23]. 
Other groups have described changes in the expression 
of  several matrix metalloproteinases (MMP-2, MMP-7, 
MMP­9), and extensive staining of  β(Ⅲ)­tubulin, a major 
constituent of  microtubules, all suggestive of  invasion 
and migration potential of  tumor buds[24-26]. Together with 
loss of  epithelial­like properties and cell­cell adhesion, in 
addition to the ability to re­differentiate at distant sites, 
the hypothesis that tumor buds could represent putative 
migrating stem cells is not far­fetched.
Phenotypic characterization of  colorectal CSC is still 
debated although putative CSC populations have been 
identified in several solid tumors based on functional stem 
cell­like properties and expression of  specific markers. 
Recently, 4 such markers have been proposed for colorectal 
cancer; CD133, a glycoprotein expressed on CD34+ stem 
and progenitor cells in fetal liver, endothelial precursors 
and fetal neural stem cells; CD44s, an adhesion molecule 
with roles in signaling, migration, and homing, EpCAM, 
a homophilic Ca2+­independent cell adhesion molecule 
expressed on the basolateral surfaces of  most epithelial 
cells; and CD166 or activated leukocyte cell adhesion 
molecule (ALCAM) known as a mesenchymal stem cell 
marker[27]. Other putative stem cell markers have also 
generated interest in other tumor types including ABCG5, 
a member of  the ATP binding cassette family involved in 
transport of  sterol and other lipids, ALDH1, a member of  
the aldehyde dehydrogenase family of  enzymes with roles 
in proliferation, differentiation, and survival, CD24, an 
adhesion molecule and ligand for P­selectin, and CD90, a 
mediator of  thymocyte adhesion to thymic stroma[28].
Considering the apparent stem cell­like properties 
of  tumor buds and adverse effect of  budding on clinical 
outcome, we hypothesized that expression of  a subset of  
these 8 putative stem cell markers could have significant 
implications for prognosis in patients with positive tumor 
budding. Thus, the aim of  this study was to determine the 
impact of  CD166, CD44s, EpCAM, ALDH1, CD133, 
CD24, CD90, and ABCG5 expressed within tumor buds 
on prognosis in patients with colorectal cancer.
MATERIALS AND METHODS
Patients
Three hundred patients with pre­operatively untreated 
tumors who underwent tumor resection between 1987 
and 1996 at the University Hospital of  Basel, Switzerland 
were initially included in this study. These patients were 
randomly selected from a larger previously described 
cohort of  938 colorectal cancer patients with full clinico­
pathological information[29]. Histopathological features 
were re­reviewed from the corresponding hematoxylin and 
eosin slides by an experienced gastrointestinal pathologist 
(LT) and included histological subtype, pT classification, 
pN classification, tumor grade, and vascular invasion. 
Tumor border configuration and peritumoral lymphocytic 
inflammation were diagnosed according to Jass et al[30]. 
Clinical data were retrieved from patient reports including 
age at diagnosis, tumor diameter, and tumor location. The 
clinical endpoint of  interest was cancer­specific survival 
time. Censored observations included patients who died 
for reasons other than colorectal cancer, who were alive or 
who were lost to follow­up. The study design is outlined in 
Figure 1.
Specimen characteristics 
The paraffin-embedded colorectal cancer resection speci-
mens for all 300 patients were retrieved from the archives 
of  the Institute of  Pathology, University Hospital of  Basel 
as well as at the Institute of  Clinical Pathology, Basel, 
Switzerland. The use of  material for this study was appro­
ved by the local ethics committee of  the University of  Basel. 
Assay methods
Immunohistochemistry for CK22 staining: All 
300 specimens were cut at 4 μm and underwent immu­
nostaining for CK22, a marker of  epithelial cells that 
served to highlight areas of  tumor budding, and which 
is routinely performed in our laboratories for diagnostic 
purposes. Briefly, tissues were de­waxed and re­hydrated 
in dH2O. Following pressure cooker­mediated antigen 
retrieval in 0.001 mol/L ethylenediaminetetraacetic acid 
pH 8.0, endogenous peroxidase activity was blocked using 
0.5% H2O2. Sections were incubated with 10% normal 
733 February 14, 2010|Volume 16|Issue 6|WJG|www.wjgnet.com
goat serum for 20 min. After incubation with primary 
antibody (CK22 polyclonal, Genetex, Inc., 1:100), sections 
were incubated with horseradish peroxidase­conjugated 
secondary antibody (DakoCytomation) for 30 min at 
room temperature, immersed in amino­ethylcarbazole 
(DakoCytomation) for 30 min, and counterstained with 
hematoxylin. 
Selection of  densest budding cases: All 300 cases were 
evaluated using a 10 × magnification for the presence of  
tumor budding (AL). Since this study was designed to 
focus on expression of  putative stem cell markers within 
the tumor buds themselves, cases with the densest number 
of  budding cells were selected for the analysis (n = 101). 
These 101 cases were then carefully re­scored for tumor 
budding according to the method proposed by Ueno 
et al[11]. Briefly, the tumor border was scanned at 10 × 
power and the area of  most dense budding identified. In 
the center of  this area, tumor buds (single cells or clusters 
of  up to 5 cells) were counted at 20 × magnification. In 
order to locate this same region of  dense budding on 
serial sections, the area was circled with a felt­tip pen. The 
clinico­pathological features for these 101 patients are 
outlined in Table 1.
Immunohistochemistry for putative stem cell markers: 
Following a similar protocol as described above, the 101 
cases with densest tumor budding were immunostained for 
CD166 (clone 110G/07; 1:200; Novocastra), CD44s (clone 
DF1485; 1:50; Dako), EpCAM (clone VU-1D9; 1:200; Cell 
Signaling), ALDH1 (isoform α1, clone Polyclonal; 1:500; 
AbCam), CD133 (clone 24139; 1:100; Cell Signaling), 
ABCG5 (1:200, Sigma­Aldrich), CD90 (clone 5E10, 1:100, 
BD Pharmingen), CD24 (clone SN3B, Neomarkers, 
1:100). CD133, CD166, CD44, CD24, CD90, EpCAM, 
and ABCG5 were evaluated for both membrane and 
cytoplasmic staining; ALDH1 was exclusively evaluated 
in the cytoplasm of  tumor buds. The number of  CD166, 
CD44s, EpCAM, ALDH1, CD133, CD24, CD90, and 
ABCG5 positive tumor buds was then evaluated in the 
area of  densest tumor budding as determined by CK22 
staining. 
Statistical analysis
Univariate survival analysis was carried out using the 
Kaplan­Meier method and log rank test. Two multivariable 
Cox regression analyses were performed. First, to test 
the independent prognostic value of  tumor budding, the 
effects of  pT stage, pN stage, tumor grade, and vascular 
invasion were adjusted for. Subsequently, because of  the 
small number of  positive cases, only 2 variables could be 
entered into the multivariable Cox regression analysis along 
with positive expression of  the protein in tumor buds, 
hence pT classification and pN classification were selected. 
The assumption of  proportional hazards was verified 
prior to this analysis. Hazard ratios (HR) and 95% CI were 
obtained to determine the prognostic effect of  positive 
cases adjusting for pT and pN. Kendall’s correlation 
coefficient (r) was obtained for correlation analysis of  
markers. P < 0.05 was considered statistically significant.
RESULTS
Prognostic value of tumor budding
In order to confirm the prognostic value of  tumor 
budding in our series, cases were divided into 3 groups 
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Table 1  Patient characteristics (n  = 101)
Clinico-pathological features Frequency n  (%)
Gender (n = 101) Female 63 (62.4)
Male 38 (37.6)
Tumor location (n = 101) Left-sided 64 (63.4)
Right-sided 37 (36.6)
Histological subtype (n = 101) Mucinous 7 (6.9)
Non-mucinous 94 (93.1)
pT classification (n = 99) pT1-2 16 (16.2)
pT3-4 83 (83.8)
pN classification (n = 100) pN0 52 (52.0)
pN1-2 48 (48.0)
Tumor grade (n = 99) G1-2 92 (92.9)
G3 7 (7.1)
Vascular invasion (n = 99) Absence 80 (80.8)
Presence 19 (19.2)
Tumor border configuration 
(n = 99)
Pushing 23 (23.2)
Infiltrating 76 (76.8)
Peritumoral lymphocytic 
inflammation (n = 99)
Absent 79 (79.8)
Present 20 (20.2)
Age (n = 101) Mean (range) 67.4 (41-89)
Tumor diameter (n = 101) Mean (range)   54.9 (20-170)
5-year survival rate (n = 101) % (95% CI) 69.3 (59-78)
300 colorectal cancer patients randomly selected from 
a well-characterized cohort of patients
Retrieval of paraffin-embedded colorectal cancer resections
Immunohistochemistry for CK22
(to facilitate identification of tumor buds)
Review of 300 cases and selection
of 101 cancers with densest tumor budding
Identification of the one area of densest tumor budding
Immunohistochemistry for 
CD133, CD166, CD24, CD44s, CD90, EpCAM, ALDH1, and ABCG5 
Evaluation of protein marker expression 
in area of densest tumor budding
Survival time analysis and correlation of significant markers
Figure 1  Study design.
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based on the distribution of  number of  tumor buds: those 
with < 40 buds, between 41-60 buds, and finally those 
with > 60 buds per 20 × field. The greater the number of  
tumor buds the more unfavorable was the prognosis both 
in univariate (P < 0.001) and multivariable analysis with 
pT, pN, tumor grade, and vascular invasion (HR: 1.6, 95% 
CI: 1.2­2.1).
Expression of putative stem cell markers within tumor 
buds
CK22 staining was used to identify regions of  densest 
tumor budding with epithelial cells exclusively immu­
noreactive for the protein. Staining for ABCG5, ALDH1, 
CD133, CD166, CD24, and CD44s could be observed 
in both tumor cells and inflammatory or stromal cells. 
EpCAM staining was predominantly limited to expression 
in tumor cells whereas CD90 was almost always expressed 
by stromal cells and only in 3 cases in the tumor itself. 
Marker expression was then evaluated in the area of  
densest budding. Representative immunostains for all 
markers are shown in Figure 2. Only one case (1.03%) 
was positive for CD90, while 5 (5.1%) and 6 (6.1%) cases 
were positive for CD44s and CD133, respectively. On 
the other hand, a considerably larger number of  positive 
cases was found to express ALDH1 (16/97, 16.5%), 
CD24 (16/99, 16.2%) and CD166 (34/100, 34%). Finally, 
ABCG5 and EpCAM staining were frequent events 
with 39/97 (40.2%) and 69/100 (69%) positive cases, 
respectively (Figure 3). 
Prognostic differences with putative stem cell marker 
expression in tumor buds
No relationship between survival time and ALDH1, CD24 
and CD166 was observed. Patients with positive EpCAM 
or ABCG5 within tumor buds had a significantly poorer 
outcome in comparison to patients with no expression 
of  these markers (P = 0.023 and P = 0.038, respectively) 
(Figure 4). Multivariable analysis was performed for 
EpCAM and ABCG5 along with pT and pN classification. 
EpCAM maintained its significant association with a 
negative effect on outcome (HR: 2.64, 95% CI: 1.0-6.9, P 
= 0.048), adjusted for pT and pN classification, a result 
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Figure 2  Immunohistochemical expression of putative cancer stem cell markers by tumor buds in colorectal cancer. A: Cytokeratin 22 staining highlighting 
the presence of tumor buds in low power magnification (5 ×); B-I: 40 × magnification. Positive expression of ABCG5 (B), ALDH1 (C), and EpCAM (D) in tumor buds 
with scattered positive staining of stromal cells, absence of staining of CD133 in tumor buds with positive staining of stromal cells (E), positive expression of CD166 in 
tumor buds with occasional positivity of stromal cells (F), absence of CD24 (G), CD44s (H), and CD90 staining (I) in tumor buds with positive stromal cell expression.
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which was also pronounced in patients with lymph node­
negative disease. Similarly, positive ABCG5 expression 
in tumor buds was again associated with a poor patient 
prognosis (P = 0.029) underlined by a relative risk of  
death of  2.22 (95% CI: 1.0-4.5) compared to patients 
lacking expression of  ABCG5. ABCG5­positive patients 
with lymph node­negative cancers had a particularly 
poor outcome in comparison to their node­negative and 
ABCG5­negative counterparts (P < 0.001). 
Correlation between EpCAM and ABCG5 expression
In order to determine whether the same cases expressed 
both EpCAM and ABCG5, the correlation between 
these markers was tested. The correlation coefficient 
r = 0.17 and P = 0.08, indicated a positive but non­
significant trend in the expression of  these markers. Of  
the 96 patients evaluable for both EpCAM and ABCG5, 
31 (32.3%) were positive and 21 (21.9%) were negative 
for both markers. We subsequently tested whether the 
combination of  these markers could additionally stratify 
patients into prognostic subgroups. Prognosis was worse 
in patients positive for both EpCAM and ABCG5 (P = 
0.013) with a relative risk of  death of  2.39 (95% CI: 1.2-4.7) 
compared to patients negative for both. In comparison to 
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Figure 3  Histogram showing the number of cases with any degree of positive staining for the 8 putative stem cells markers.
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the relative risk of  death for either EpCAM or ABCG5 
alone, the combination of  both markers does not suggest 
a superior discrimination of  patients into better and worse 
prognostic subgroups. A negative but statistically non­
significant correlation between CD44s and EpCAM (r = 
­0.15, P = 0.145) and ABCG5 (r = ­0.1, P = 0.328) was 
observed.
DISCUSSION
In this study we evaluated 8 of  the most promising puta­
tive cancer stem cell markers CD166, CD44s, EpCAM, 
ALDH1, CD133, CD24, CD90, and ABCG5 and their 
expression in colorectal tumor buds using 101 whole 
tissue sections from a well­characterized cohort of  
patients. Our main findings suggest that positive expres-
sion of  EpCAM and ABCG5 within tumor buds is a 
frequent event and may confer a significant and adverse 
prognosis in patients with colorectal cancer, particularly in 
lymph node­negative patients expressing ABCG5.
Several of  these putative CSC markers have previously 
been evaluated in tumor buds. Horst et al[31] assessed 
CD133 in colorectal cancers using 3 different antibodies. 
They reported pronounced expression of  CD133 in 
tumor glands close to the invasive margin but restricted 
to glandular differentiated cells and a general lack of  
CD133 in the tumor buds themselves. They further 
found that nuclear β­catenin expression and CD133 were 
not correlated and that the 2 protein markers may stain 
different, yet overlapping populations of  tumor cells[32]. 
Our results of  only a few CD133­positive tumor budding 
cases and no prognostic differences between patients with 
CD133­positive and ­negative tumor budding are in line 
with these findings. Investigating rectal cancers, Gosens 
et al[33] found strong membranous EpCAM staining in 
the tumor center and a progressive loss at the tumor 
front associated with high tumor grade, tumor budding, 
and a poor local and distant recurrence­free survival. 
This was also accompanied by a concomitant increase in 
cytoplasmic EpCAM staining as well as overexpression 
of  β­catenin. We also observed a pronounced loss of  
EpCAM toward the invasive tumor front, particularly 
in tumors with infiltrating margins, as well as a shift in 
localization of  EpCAM expression from membrane to 
cytoplasm. The findings of  this study indicate that despite 
this loss towards the border, patients with EpCAM­
positive tumor buds have a most unfavorable survival 
time, a result which was maintained in multivariable 
analysis. Although EpCAM, like CD44, is known for 
its cell­adhesion function, it seems to have versatile 
roles in signaling, cell migration, proliferation, and 
differentiation depending on the microenvironment[34]. 
In the normal epithelium, EpCAM supports adhesion, 
whereas in carcinoma it seems to prevent strong cell­cell 
adhesion, enabling cell migration and metastasis similar to 
E­cadherin. The intracellular localization of  EpCAM and 
its identification by immunohistochemistry may represent 
differential roles of  this protein in colorectal cancer 
progression and partially explain why, despite loss of  
expression from normal at tumor center to tumor border, 
the positive expression in buds is linked to a poorer 
patient outcome.
Masaki et al [35] have also described associations 
between membranous CD44 and CD44v6 expression 
and a higher degree of  tumor budding. However, it 
is unclear from these studies whether expression was 
evaluated in the tumor center, then correlated with 
tumor budding or whether expression was evaluated in 
buds themselves. Our group has also previously found 
that loss of  membranous expression of  both CD44s 
and CD44v6 within the tumor center is highly correlated 
with an infiltrating tumor border configuration, a result 
which is in line with the findings of  this study showing 
only rare cases expressing CD44s in tumor buds, too few 
in fact for adequate survival analysis.
ABCG5 is a member of  the ATP­binding cassette 
subfamily G and plays a role in the efflux transport of  
cholesterol[36,37]. Its expression has been correlated with 
clinical melanoma progression and it is hypothesized to 
contribute to the refractoriness of  metastatic cancer to 
chemotherapy[38]. Indeed, specific targeting of  ABCG5 
with monoclonal antibodies appears to significantly inhibit 
cell growth. To date, ABCG5 does not appear to have 
been investigated in colorectal cancer, and moreover in 
tumor buds. However, our findings of  ABCG5 expression 
in a considerable number of  colorectal cancer tumor buds 
as well as an adverse prognosis in particular in patients 
with lymph node­negative disease suggests that the role 
of  ABCG5 in colorectal pathogenesis warrants further 
investigation.
Our results of  adverse prognosis in EpCAM­positive 
and ABCG5­positive patients may be to some extent 
affected by the lack of  information regarding cancer 
treatment. Despite this limitation, the unfavorable 
outcome associated with EpCAM and, particularly with 
ABCG5­positivity was maintained in patients with lymph 
node­negative colorectal cancers who, by today’s treatment 
guidelines, are not generally considered for adjuvant 
chemotherapy[39]. The findings of  this study regarding the 
prognostic value and expression of  EpCAM and ABCG5 
within colorectal tumor buds should be considered 
preliminary and require validation on independent patient 
cohorts. 
To summarize, in contrast to CD133, CD166, CD24, 
CD44s, CD90, and ALDH1, the expression of  putative 
stem cell markers EpCAM and ABCG5 within the tumor 
buds of  colorectal tumors are frequent events indicating 
poor prognosis. In particular, patients with lymph node­
negative disease expressing EpCAM or ABCG5 have a 
particularly unfavorable prognosis suggesting that the 
immunohistochemically analyzed EpCAM and ABCG5 in 
tumor buds may be useful biomarkers of  poor outcome 
in this subgroup of  patients. Further studies are necessary 
to address the important issue of  whether EpCAM­ or 
ABCG5­positive tumor buds indeed represent migrating 
colorectal CSC.
737 February 14, 2010|Volume 16|Issue 6|WJG|www.wjgnet.com
Hostettler I et al . ABCG5 in colorectal cancer
COMMENTS
Background
Tumor budding at the invasive tumor front of colorectal cancer is recognized 
as an important independent prognostic factor. Several lines of evidence seem 
to suggest that tumor buds may to some extent represent malignant colorectal 
cancer stem cells because of their potential for migration and re-differentiation 
locally and at sites of metastasis.
Research frontiers
Phenotypic characterization of cancer stem cells is still debated although at 
least 8 putative stem cell markers have been suggested including CD166, 
CD44s, EpCAM, ALDH1, CD133, CD24, CD90, and ABCG5. The research 
hotspot is how the expression of putative cancer stem cell markers can be 
potentially used as prognostic biomarkers in patients with colorectal cancer.
Innovations and breakthroughs
Considering the apparent stem cell-like properties of tumor buds and adverse 
effect of budding on clinical outcome, in this study the authors performed 
immunohistochemical staining of 8 promising putative cancer stem cell markers, 
namely CD166, CD44s, EpCAM, ALDH1, CD133, CD24, CD90, and ABCG5 
and assessed their expression within tumor buds to determine their frequency 
and potential prognostic significance in patients with colorectal cancer.
Applications
The study results suggest that, in contrast to CD133, CD166, CD24, CD44s, 
CD90, and ALDH1, the expression of putative cancer stem cell markers EpCAM 
and ABCG5 within the tumor buds of colorectal cancer are frequent events 
associated with poor prognosis.
Terminology
Tumor budding: single cells or clusters of up to 4 or 5 cells at the invasive 
tumor front of colorectal cancer which are diagnosed at high magnification and 
highly associated with an infiltrating tumor growth pattern. Cancer stem cells: 
tumorigenic cell populations with the potential to self-renew and differentiate.
Peer review
The study is characterized technically by an excellent application of immuno-
histochemistry and provides interesting evidence to aid in understanding the 
correlation between cancer stem cell markers in the invasive front of colorectal 
cancer and prognosis.
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